Acute Myelogenous Leukemia
The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.
There is warranted excitement for AG-221, a drug recently granted fast track designation by the FDA for acute myelogenous leukemia (AML).
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
At least one nonsynonymous mutation in a gene relevant for pathogenesis seen in nearly all cases
Assessment of minimal residual disease provides prognostic information for children with AML.
Relapse of acute myeloid leukemia (AML) is associated with acquisition of new mutations and clonal evolution.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy